Clinuvel Pharmaceuticals Ltd: Vitiligo and Operational Update
Clinuvel Pharmaceuticals Ltd: Annual Results Webinar
Clinuvel Pharmaceuticals Ltd: Afamelanotide Assists DNA Repair Response Following UVR
Clinuvel Pharmaceuticals Ltd: SCENESSE European Orphan Drug Designation for VP
Clinuvel Pharmaceuticals Ltd: afamelanotide in fair-skinned Parkinsons patients
Clinuvel Pharmaceuticals Ltd: CLINUVEL Newsletter III - June 2024
Clinuvel Pharmaceuticals Ltd: CLINUVEL withdraws label expansion for adolescent EPP
Clinuvel Pharmaceuticals Ltd: CLINUVEL and Valentech enter Latin American partnership
Clinuvel Pharmaceuticals Ltd: SCENESSE European Orphan Drug Designation for XP
Clinuvel Pharmaceuticals Ltd: CLINUVEL Newsletter II - March 2024
Clinuvel Pharmaceuticals Ltd: Update - Notification of buy-back - CUV
Clinuvel Pharmaceuticals Ltd: Notification of buy-back - CUV
Clinuvel Pharmaceuticals Ltd: CLINUVEL initiates on market share buy-back program
Clinuvel Pharmaceuticals Ltd: New case of SCENESSE efficacy in vitiligo presented at AAD
Clinuvel Pharmaceuticals Ltd: SCENESSE Presented at American Academy of Dermatology
Clinuvel Pharmaceuticals Ltd: SCENESSE provides photoprotection in variegate porphyria
Clinuvel Pharmaceuticals Ltd: Final Director's Interest Notice
Clinuvel Pharmaceuticals Ltd: Half Year Results Webinar Recording
Clinuvel Pharmaceuticals Ltd: Half Year Results Investor Webinar
Clinuvel Pharmaceuticals Ltd: Chair Elect Letter
No Data